10-Sep-2024 10:40 AM CST - YAHOO!Finance Viatris Announces the Pricing Terms of Pending Any and All Cash Tender Offers Viatris Inc. (NASDAQ: VTRS, "Viatris" or the "Company") announced today the pricing terms of the previously announced cash tender offers (the "Any and All Tender Offers" and each, an "Any and All Tender Offer") of Viatris and its subsidiary Mylan Inc.
9-Aug-2024 8:30 AM CST - YAHOO!Finance Compared to Estimates, Viatris (VTRS) Q2 Earnings: A Look at Key Metrics The headline numbers for Viatris (VTRS) give insight into how the company performed in the quarter ended June 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
9-Aug-2024 12:05 AM CST - YAHOO!Finance Decoding Viatris Inc (VTRS): A Strategic SWOT Insight Detailed examination of Viatris Inc's financial performance, with a focus on recent divestitures and acquisitions. Strategic evaluation of Viatris Inc's market position and future outlook in the competitive pharmaceutical landscape.
8-Aug-2024 11:40 PM CST - Business Insider Analyst Maintains Sell Rating on Viatris Citing Long-Term Revenue Concerns and Growth Challenges Viatris (VTRS - Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Jason Gerberry from Bank of America Securities reiterated a Sell rating on the stock and has a $12.00 price target. Jason Gerberry ...
8-Aug-2024 10:52 AM CST - YAHOO!Finance Why Viatris Stock Is Jumping Today Viatris also raised its full-year new product revenue forecast. It now expects a range of $500 million to $800 million, up from the previous projection of $450 million to $550 million.
8-Aug-2024 10:27 AM CST - The Motley Fool Viatris Reports Mixed Q2 Results Viatris reported mixed second-quarter 2024 results, with a net loss contrasting new product growth and strategic divestitures.
10-Sep-2024 10:40 AM CST - YAHOO!Finance Viatris Announces the Pricing Terms of Pending Any and All Cash Tender Offers Viatris Inc. (NASDAQ: VTRS, "Viatris" or the "Company") announced today the pricing terms of the previously announced cash tender offers (the "Any and All Tender Offers" and each, an "Any and All Tender Offer") of Viatris and its subsidiary Mylan Inc.
9-Aug-2024 8:30 AM CST - YAHOO!Finance Compared to Estimates, Viatris (VTRS) Q2 Earnings: A Look at Key Metrics The headline numbers for Viatris (VTRS) give insight into how the company performed in the quarter ended June 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
9-Aug-2024 12:05 AM CST - YAHOO!Finance Decoding Viatris Inc (VTRS): A Strategic SWOT Insight Detailed examination of Viatris Inc's financial performance, with a focus on recent divestitures and acquisitions. Strategic evaluation of Viatris Inc's market position and future outlook in the competitive pharmaceutical landscape.
8-Aug-2024 11:40 PM CST - Business Insider Analyst Maintains Sell Rating on Viatris Citing Long-Term Revenue Concerns and Growth Challenges Viatris (VTRS - Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Jason Gerberry from Bank of America Securities reiterated a Sell rating on the stock and has a $12.00 price target. Jason Gerberry ...
8-Aug-2024 10:52 AM CST - YAHOO!Finance Why Viatris Stock Is Jumping Today Viatris also raised its full-year new product revenue forecast. It now expects a range of $500 million to $800 million, up from the previous projection of $450 million to $550 million.
8-Aug-2024 10:27 AM CST - The Motley Fool Viatris Reports Mixed Q2 Results Viatris reported mixed second-quarter 2024 results, with a net loss contrasting new product growth and strategic divestitures.
